Cargando…
Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study
We evaluated the efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents (6–17 years) with autism spectrum disorder (ASD) in a randomized, double-blind, placebo-controlled 8-week study in Japan. Patients received flexibly dosed aripiprazole (1–15 mg/day) or p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617873/ https://www.ncbi.nlm.nih.gov/pubmed/28004215 http://dx.doi.org/10.1007/s10578-016-0704-x |
_version_ | 1783267058647040000 |
---|---|
author | Ichikawa, Hironobu Mikami, Katsunaka Okada, Takashi Yamashita, Yushiro Ishizaki, Yuko Tomoda, Akemi Ono, Hiroaki Usuki, Chiharu Tadori, Yoshihiro |
author_facet | Ichikawa, Hironobu Mikami, Katsunaka Okada, Takashi Yamashita, Yushiro Ishizaki, Yuko Tomoda, Akemi Ono, Hiroaki Usuki, Chiharu Tadori, Yoshihiro |
author_sort | Ichikawa, Hironobu |
collection | PubMed |
description | We evaluated the efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents (6–17 years) with autism spectrum disorder (ASD) in a randomized, double-blind, placebo-controlled 8-week study in Japan. Patients received flexibly dosed aripiprazole (1–15 mg/day) or placebo. Ninety-two patients were randomized to placebo (n = 45) or aripiprazole (n = 47). Aripiprazole produced a significant improvement in the mean parent/caregiver-rated Aberrant Behavior Checklist Japanese Version irritability subscale score relative to placebo from week 3 through week 8. Administration of aripiprazole provided significantly greater improvement in the mean clinician-rated Clinical Global Impression-Improvement scores than placebo from week 2 through week 8. All patients randomized to aripiprazole completed the study, and no serious adverse events were reported. Three patients in placebo group discontinued. Aripiprazole was effective and generally safe and well-tolerated in the treatment of irritability associated with ASD in Japanese children and adolescents. |
format | Online Article Text |
id | pubmed-5617873 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-56178732017-10-12 Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study Ichikawa, Hironobu Mikami, Katsunaka Okada, Takashi Yamashita, Yushiro Ishizaki, Yuko Tomoda, Akemi Ono, Hiroaki Usuki, Chiharu Tadori, Yoshihiro Child Psychiatry Hum Dev Original Article We evaluated the efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents (6–17 years) with autism spectrum disorder (ASD) in a randomized, double-blind, placebo-controlled 8-week study in Japan. Patients received flexibly dosed aripiprazole (1–15 mg/day) or placebo. Ninety-two patients were randomized to placebo (n = 45) or aripiprazole (n = 47). Aripiprazole produced a significant improvement in the mean parent/caregiver-rated Aberrant Behavior Checklist Japanese Version irritability subscale score relative to placebo from week 3 through week 8. Administration of aripiprazole provided significantly greater improvement in the mean clinician-rated Clinical Global Impression-Improvement scores than placebo from week 2 through week 8. All patients randomized to aripiprazole completed the study, and no serious adverse events were reported. Three patients in placebo group discontinued. Aripiprazole was effective and generally safe and well-tolerated in the treatment of irritability associated with ASD in Japanese children and adolescents. Springer US 2016-12-21 2017 /pmc/articles/PMC5617873/ /pubmed/28004215 http://dx.doi.org/10.1007/s10578-016-0704-x Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Ichikawa, Hironobu Mikami, Katsunaka Okada, Takashi Yamashita, Yushiro Ishizaki, Yuko Tomoda, Akemi Ono, Hiroaki Usuki, Chiharu Tadori, Yoshihiro Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study |
title | Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study |
title_full | Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study |
title_fullStr | Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study |
title_full_unstemmed | Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study |
title_short | Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study |
title_sort | aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in japan: a randomized, double-blind, placebo-controlled study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617873/ https://www.ncbi.nlm.nih.gov/pubmed/28004215 http://dx.doi.org/10.1007/s10578-016-0704-x |
work_keys_str_mv | AT ichikawahironobu aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy AT mikamikatsunaka aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy AT okadatakashi aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy AT yamashitayushiro aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy AT ishizakiyuko aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy AT tomodaakemi aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy AT onohiroaki aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy AT usukichiharu aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy AT tadoriyoshihiro aripiprazoleinthetreatmentofirritabilityinchildrenandadolescentswithautismspectrumdisorderinjapanarandomizeddoubleblindplacebocontrolledstudy |